On Jul 20, 2021 OriCiro Genomics raised ¥800 million in Series B financing led by The University of Tokyo Edge Capital Partners (UTEC) with the participation of ITOCHU Technology Ventures (ITV). OriCiro has also received a ¥200 million long-term loan from Japan Finance Corporation (JFC), a government-affiliated financial institution

About the company: OriCiro Genomics is located in Tokyo, Japan, Asia. OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene and cell-based therapies and synthetic biology. OriCiro’s proprietary technology is positioned to unlock the possibility of advanced therapy and synthetic biology by providing a powerful tool used for research, development and manufacturing in multiple industries including pharmaceutical, diagnostics, agriculture and food sectors. 

Company website: https://www.ec.oriciro.com/